Managing community acquired pneumonia in the elderly–the next generation of pharmacotherapy on the horizon

B. Amalakuhan, K. Echevarria, Marcos Restrepo

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Community acquired pneumonia (CAP) is associated with high rates of morbidity and mortality, especially among the elderly. Antibiotic treatment for CAP in the elderly is particularly challenging for many reasons, including compliance issues, immunosuppression, polypharmacy and antimicrobial resistance. There are few available antibiotics that are able to address these concerns. Areas covered: After a systematic review of the current literature, we describe seven novel antibiotics that are currently in advanced stages of development (phase 3 and beyond) and show promise for the treatment of CAP in those over the age of 65. These antibiotics are: Solithromycin, Pristinamycin, Nemonaxacin, Lefamulin, Omadacycline, Ceftobiprole and Delafloxacin. Using a novel conceptual framework designed by the present authors, known as the ‘San Antonio NIPS model’, we evaluate their strengths and weaknesses based on their ability to address the unique challenges that face the elderly. Expert opinion: All seven antibiotics have potential value for effective utilization in the elderly, but to varying degrees based on their NIPS model score. The goal of this model is to reorganize a clinician’s focus on antibiotic choices in the elderly and bring attention to a seldom discussed topic that may potentially become a health-care crisis in the next decade.

Original languageEnglish (US)
Pages (from-to)1039-1048
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number11
DOIs
StatePublished - Jul 24 2017

Fingerprint

Pneumonia
Anti-Bacterial Agents
Drug Therapy
Pristinamycin
Polypharmacy
Expert Testimony
Immunosuppression
Compliance
Morbidity
Delivery of Health Care
Mortality
Therapeutics
N-(4-isothiocyanatophenethyl)spiperone

Keywords

  • CAP
  • Ceftobiprole
  • community-acquired pneumonia
  • Lefamulin
  • Nemonaxacin
  • Omadacycline
  • pharmacotherapy
  • Pristinamycin
  • San Antonio NIPS Model
  • Solithromycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Managing community acquired pneumonia in the elderly–the next generation of pharmacotherapy on the horizon. / Amalakuhan, B.; Echevarria, K.; Restrepo, Marcos.

In: Expert Opinion on Pharmacotherapy, Vol. 18, No. 11, 24.07.2017, p. 1039-1048.

Research output: Contribution to journalReview article

@article{1b40d86c9f884ab89e372353fa36a946,
title = "Managing community acquired pneumonia in the elderly–the next generation of pharmacotherapy on the horizon",
abstract = "Introduction: Community acquired pneumonia (CAP) is associated with high rates of morbidity and mortality, especially among the elderly. Antibiotic treatment for CAP in the elderly is particularly challenging for many reasons, including compliance issues, immunosuppression, polypharmacy and antimicrobial resistance. There are few available antibiotics that are able to address these concerns. Areas covered: After a systematic review of the current literature, we describe seven novel antibiotics that are currently in advanced stages of development (phase 3 and beyond) and show promise for the treatment of CAP in those over the age of 65. These antibiotics are: Solithromycin, Pristinamycin, Nemonaxacin, Lefamulin, Omadacycline, Ceftobiprole and Delafloxacin. Using a novel conceptual framework designed by the present authors, known as the ‘San Antonio NIPS model’, we evaluate their strengths and weaknesses based on their ability to address the unique challenges that face the elderly. Expert opinion: All seven antibiotics have potential value for effective utilization in the elderly, but to varying degrees based on their NIPS model score. The goal of this model is to reorganize a clinician’s focus on antibiotic choices in the elderly and bring attention to a seldom discussed topic that may potentially become a health-care crisis in the next decade.",
keywords = "CAP, Ceftobiprole, community-acquired pneumonia, Lefamulin, Nemonaxacin, Omadacycline, pharmacotherapy, Pristinamycin, San Antonio NIPS Model, Solithromycin",
author = "B. Amalakuhan and K. Echevarria and Marcos Restrepo",
year = "2017",
month = "7",
day = "24",
doi = "10.1080/14656566.2017.1340937",
language = "English (US)",
volume = "18",
pages = "1039--1048",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Managing community acquired pneumonia in the elderly–the next generation of pharmacotherapy on the horizon

AU - Amalakuhan, B.

AU - Echevarria, K.

AU - Restrepo, Marcos

PY - 2017/7/24

Y1 - 2017/7/24

N2 - Introduction: Community acquired pneumonia (CAP) is associated with high rates of morbidity and mortality, especially among the elderly. Antibiotic treatment for CAP in the elderly is particularly challenging for many reasons, including compliance issues, immunosuppression, polypharmacy and antimicrobial resistance. There are few available antibiotics that are able to address these concerns. Areas covered: After a systematic review of the current literature, we describe seven novel antibiotics that are currently in advanced stages of development (phase 3 and beyond) and show promise for the treatment of CAP in those over the age of 65. These antibiotics are: Solithromycin, Pristinamycin, Nemonaxacin, Lefamulin, Omadacycline, Ceftobiprole and Delafloxacin. Using a novel conceptual framework designed by the present authors, known as the ‘San Antonio NIPS model’, we evaluate their strengths and weaknesses based on their ability to address the unique challenges that face the elderly. Expert opinion: All seven antibiotics have potential value for effective utilization in the elderly, but to varying degrees based on their NIPS model score. The goal of this model is to reorganize a clinician’s focus on antibiotic choices in the elderly and bring attention to a seldom discussed topic that may potentially become a health-care crisis in the next decade.

AB - Introduction: Community acquired pneumonia (CAP) is associated with high rates of morbidity and mortality, especially among the elderly. Antibiotic treatment for CAP in the elderly is particularly challenging for many reasons, including compliance issues, immunosuppression, polypharmacy and antimicrobial resistance. There are few available antibiotics that are able to address these concerns. Areas covered: After a systematic review of the current literature, we describe seven novel antibiotics that are currently in advanced stages of development (phase 3 and beyond) and show promise for the treatment of CAP in those over the age of 65. These antibiotics are: Solithromycin, Pristinamycin, Nemonaxacin, Lefamulin, Omadacycline, Ceftobiprole and Delafloxacin. Using a novel conceptual framework designed by the present authors, known as the ‘San Antonio NIPS model’, we evaluate their strengths and weaknesses based on their ability to address the unique challenges that face the elderly. Expert opinion: All seven antibiotics have potential value for effective utilization in the elderly, but to varying degrees based on their NIPS model score. The goal of this model is to reorganize a clinician’s focus on antibiotic choices in the elderly and bring attention to a seldom discussed topic that may potentially become a health-care crisis in the next decade.

KW - CAP

KW - Ceftobiprole

KW - community-acquired pneumonia

KW - Lefamulin

KW - Nemonaxacin

KW - Omadacycline

KW - pharmacotherapy

KW - Pristinamycin

KW - San Antonio NIPS Model

KW - Solithromycin

UR - http://www.scopus.com/inward/record.url?scp=85024478040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024478040&partnerID=8YFLogxK

U2 - 10.1080/14656566.2017.1340937

DO - 10.1080/14656566.2017.1340937

M3 - Review article

C2 - 28598693

AN - SCOPUS:85024478040

VL - 18

SP - 1039

EP - 1048

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 11

ER -